文献速递膀胱癌与上尿路尿路上皮癌

SAUL研究主要结果:阿替利珠单抗治疗局部晚期或转移性尿路尿路上皮癌或非尿路上皮癌的多国单臂安全性研究

Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract.
PubMed 文献 · Eur Urol · 2019-03-23

SAUL是一项国际单臂安全性研究,纳入1004例局部晚期或转移性尿路尿路上皮癌或非尿路上皮癌患者,接受阿替利珠单抗1200mg每3周一次治疗。主要终点为安全性,3级及以上不良事件发生率为45%,中位总生存期8.7个月,总缓解率13%。结论认为阿替利珠单抗在真实世界经治人群中耐受性良好,疗效与既往关键试验一致。

要点

  • 3级及以上不良事件发生率为45%,最常见治疗相关3级及以上不良事件为乏力、虚弱、结肠炎和高血压(各1%)。
  • 中位总生存期8.7个月,6个月总生存率60%,中位无进展生存期2.2个月,总缓解率13%(完全缓解3%)。
  • 在类似IMvigor211入组条件的患者中,中位总生存期10.0个月,6个月总生存率65%。

核心结论

  • SAUL研究证实阿替利珠单抗在真实世界经治尿路癌人群中具有耐受性,总疗效及IMvigor211类似亚组疗效与既往关键抗PD-L1/PD-1尿路癌试验一致。
  • 这些结果支持在尿路癌中使用阿替利珠单抗,包括治疗选择有限的患者。

研究设计与样本

  • 多国单臂安全性研究,2016年11月至2018年3月入组1004例局部晚期或转移性尿路尿路上皮癌或非尿路尿路上皮癌患者,中位随访12.7个月。
  • 入组条件为不可手术、局部晚期或转移性疾病在一至三线既往治疗后进展;肾功能损害、已治疗的中枢神经系统转移或稳定控制的自身免疫病患者可入组。
  • 10%患者ECOG体能状态评分为2,98%患者接受过铂类治疗(Clinicaltrials.gov注册号:NCT02928406)。

主要发现

  • 中位治疗持续时间2.8个月(范围0-19),22%患者仍在治疗,8%因毒性停药。
  • 3级及以上不良事件发生率为45%;最常见的3级及以上治疗相关不良事件为乏力、虚弱、结肠炎和高血压,各占1%。
  • 中位总生存期8.7个月(95%CI 7.8-9.9),6个月总生存率60%(95%CI 57-63%),中位无进展生存期2.2个月(95%CI 2.1-2.4),总缓解率13%(95%CI 11-16%),其中完全缓解3%。
  • 在类似IMvigor211入组条件的患者中(排除ECOG体能状态评分2及其他IMvigor211排除标准),中位总生存期10.0个月(95%CI 8.8-11.9),6个月总生存率65%(95%CI 61-69%)。

临床怎么用

  • 作者认为,这些结果支持在尿路癌中使用阿替利珠单抗,包括治疗选择有限的患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Atezolizumab, a humanised monoclonal antibody targeting PD-L1, is approved for locally advanced/metastatic urothelial carcinoma. SAUL evaluated atezolizumab in a broader, pretreated population, including patients ineligible for the pivotal IMvigor211 phase 3 trial of atezolizumab. OBJECTIVE: To determine the safety and efficacy of atezolizumab in an international real-world setting. DESIGN, SETTING, AND PARTICIPANTS: Between November 2016 and March 2018 (median follow-up 12.7mo), 1004 patients with locally advanced or metastatic urothelial or nonurothelial urinary tract carcinoma who experienced progression during or after one to three prior therapies for inoperable, locally advanced, or metastatic disease were enrolled. Patients with renal impairment, treated central nervous system metastases, or stable controlled autoimmune disease were eligible; 10% had Eastern Cooperative Oncology Group performance status (ECOG PS) 2 and 98% were platinum pretreated (Clinicaltrials.gov: NCT02928406). INTERVENTION: Atezolizumab 1200mg every 3wk until progression or unacceptable toxicity. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary endpoint was safety. Secondary efficacy endpoints included overall survival (OS), progression-free survival (PFS), and overall response rate (ORR). RESULTS AND LIMITATIONS: The median treatment duration was 2.8mo (range 0-19); 22% remained on treatment and 8% discontinued because of toxicity. Grade ≥3 adverse events occurred in 45% of patients. The most common grade ≥3 treatment-related adverse events were fatigue, asthenia, colitis, and hypertension (each in 1%). Median OS was 8.7mo (95% confidence interval [CI] 7.8-9.9). The 6-mo OS rate was 60% (95% CI 57-63%), median PFS was 2.2mo (95% CI 2.1-2.4), and the ORR was 13% (95% CI 11-16%; 3% complete responses). Among IMvigor211-like patients (excluding ECOG PS 2 and other IMvigor211 exclusion criteria), median OS was 10.0mo (95% CI 8.8-11.9) and 6-mo OS was 65% (95% CI 61-69%). CONCLUSIONS: SAUL confirms the tolerability of atezolizumab in a real-world pretreated population with urinary tract carcinoma. Efficacy overall and in the IMvigor211-like subgroup is consistent with previous pivotal anti-PD-L1/PD-1 urothelial carcinoma trials. These results support the use of atezolizumab in urinary tract carcinoma, including patients with limited treatment options. PATIENT SUMMARY: In this international study we investigated the efficacy and safety of atezolizumab treatment for advanced urinary tract cancer in a large population of pretreated patients, including those who would not normally be candidates for clinical trials. Patients tolerated the treatment well, even if they had autoimmune disease, were being treated with corticosteroids, or had disease that had spread to their brain. Life expectancy in this study for patients typical of everyday clinical practice was similar to that seen in trials that enrolled only selected fitter patients.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Sternberg CN, Loriot Y, James N, et al. Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract. Eur Urol. 2019. PMID: 30910346. doi:10.1016/j.eururo.2019.03.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。